Oncology
Page 1 • 12 itemsGlobal oncology market intelligence for pharma BD, investors, and analysts. Track drug approvals, clinical trials, and competitive landscapes.
FDA Approval for Pfizer's Breast Cancer Drug: Vepdegestrant
The FDA has granted approval for Pfizer and Arvinas' novel breast cancer drug, vepdegestrant. This marks a significant new treatment option for patients with advanced or metastatic HR-positive, HER2-negative breast cancer who have exhausted prior endocrine therapies.
African Medicines Agency impact: Harmonizing Clinical Trials in Africa
The African Medicines Agency is transforming clinical trials in Africa, streamlining processes for drug approvals and improving access to essential medicines.
COFEPRIS Approval Pathway: Insights on Novel Immunotherapies for Advanced Melanoma
This article delves into the COFEPRIS approval process for innovative immunotherapies targeting advanced melanoma, highlighting key insights and drug developments.
Cancer Immunotherapies UAE: Regulatory and Access Insights 2025
This article provides essential insights into the regulatory landscape and access to cancer immunotherapies in the UAE, focusing on key drugs and future trends.
Bispecific Antibodies in Hematological Malignancies: Teclistamab, Mosunetuzumab & Epcoritamab FDA Review
This article delves into the FDA review of bispecific antibodies teclistamab, mosunetuzumab, and epcoritamab for hematological malignancies.
FDA Approvals NSCLC 2025: Market Impact & New Treatment Options
Discover the latest FDA approvals for NSCLC in 2025, focusing on new treatment options like XYZ Drug and their significant market implications.
FDA Accelerated Approvals Oncology: 2026 Policy Review & Zongertinib Case
This article delves into the FDA's 2026 policy review on accelerated approvals in oncology, focusing on the case of Zongertinib for lung cancer therapy.
KRAS G12C Inhibitors NSCLC: Market Analysis of Sotorasib & Adagrasib
This article delves into the market dynamics of KRAS G12C inhibitors, Sotorasib and Adagrasib, highlighting their roles in non-small cell lung cancer treatment.
FDA Approval Elranatamab: Efficacy, Safety & Market Impact in RRMM
Elranatamab has gained FDA approval for relapsed/refractory multiple myeloma, showcasing promising efficacy and safety, and is set to impact the market significantly.
CAR-T Therapy Clinical Trials: Insights from ASCO 2026 and FDA Approval Implications
Discover the latest insights on CAR-T therapy from ASCO 2026 and understand the potential implications of FDA approval for innovative cancer treatments.
FDA's New AI Validation Framework in Oncology Drug Development
The FDA's new AI validation framework aims to streamline oncology drug development, ensuring more effective cancer therapies through advanced technology.
FDA Companion Diagnostic Policies: Market Evolution in Precision Oncology
This article delves into the evolving FDA companion diagnostic policies and their impact on precision oncology, focusing on drugs like Keytruda for lung cancer.